You are on page 1of 4

7/3/2017 Pharma 2020: Russia Marching Towards Self-sufficiency?

+7 (495) 726-26-69 Marksistsky lane 6, office 221, Moscow, 109147, Russia


Home Industry News Pharma 2020: Russia Marching Towards Self-sufficiency?

Start searching...

Contributor: Yulia Privolnev, Senior Analyst, Global Market Access Insights

Published on: 28 January, 2016
Category: DRG Blog
Filed under:Domestic Manufacturing, Europe, Global Market Access, Payers, Pharma 2020, Pricing & Reimbursement, Russia, Yulia Taj Pharma Launches VENOSTOR
(Diosmin/Hesperidin Tablets) Unique
Although perhaps better known outside its borders these days for foreign policy moves, Russia has quietly become

Natural Formula
one of the most dynamic market access environments this year as
President Vladimir Putin has sought to generate popular support via Pharmaceuticals in Russia Pharma
healthcare endeavors. Moreover, hes sought to build up Russias domestic
pharmaceutical manufacturing base to encourage self-sufficiency, and 2020: From vision to decision |

guard against currency volatility and sanctions.

Speaking at the Russian Popular Fronts forum for Quality and Affordable
Pharma 2020: Russia Marching Towards
Medicine in September 2015, Putin reiterated Russias domestic
manufacturing goals, as outlined in the Pharma 2020 strategy, and Self-sufficiency?
updated on the success of the strategy thus far. Pharma 2020, launched in
Pharma 2020: Russia
2009, asserted the development of a strong domestic pharmaceutical What Russian pharma requires to grow

industry as a top political priority for Russia. The core goal of Pharma2020
is an ambitious desire to raise domestically produced drugs market share from 22% of sales in 2010 to 50% by 2020. Furthermore,
drugs manufactured in Russia should account for at least 90% of drugs on the List of Vital and Essential Medicines (ZHNVLP). Lastly, Russian pharmaceutical market may grow
the initiative aims to launch an import substitution policy that would see Russia producing highly innovative drugs that currently have
no Russian-made equivalents. Basically, the goal is self-sufficiency for Russia. by 8% in 2016

The stark need for such a strategy was highlighted in recent years, as the oil crisis devalued the Russian ruble. The economic crisis
saw some foreign manufacturers cut production of certain medications, as the ruble devaluation and strict state pricing eviscerated
profit margins.

In order to achieve the goals of Pharma 2020, the strategy has been split into three phases. The first phase lasted from 2009-2012,
and focused on the construction of new manufacturing facilities and investment in R&D. The current phase spans from 2012-2017 and
is the focused on the domestic production of generics, the implementation of an import substitution policy and progress towards
pharmaceutical self-sufficiency. The last phase, from 2018-2020, will see the strategy shift focus towards export growth.
December 2016

Pharma 2020 came at a crucial time for Russia, but has it been successful? Putin certainly thinks so. At the Quality and Affordable
April 2014
Medicine forum, he informed the enraptured audience that Russia was on pace to localize 90% of medicines currently in use in Russia
by 2018. The signs are positive for Russias domestic industry. The 2012 ZHNVLP list contained 567 drugs, with only 93 manufactured March 2014
in Russia and 267 as joint ventures between Russian and foreign companies. The December 2014 list includes 608 drugs, 413 of
which were locally manufactured. February 2014

January 2014 1/4
7/3/2017 Pharma 2020: Russia Marching Towards Self-sufficiency?
Putin did reiterate that Russias competitiveness in its own pharmaceutical industry will not be achieved with harsh protectionist
December 2013
measures. Instead of banning or prohibiting certain medicines or devices, the government aims to achieve success via import
substitution and fostering the nascent domestic industry, especially when it comes to innovative drugs. In January 2015, in part a
response to the currency crisis and as part of the second phase of Pharma 2020, the Ministry of Health announced that plans were
underway to set up domestic production for 12 drugs that were currently only available via import. Furthermore, they announced that
plans were underway to create 10 domestic forms of oncology drugs to replace currently used foreign brands.
Evidently, the second phase of Pharma2020 has been ticking along nicely. A flurry of legislation has been introduced in recent years
(details of which can be found in DRGs GMAS Russia analysis). Legislation ranges from cash subsidies of up to 50% of the cost of Health Awareness

production for companies manufacturing new drugs, to tighter definitions on what constitutes a Russian-made drug, to legislation
Industry News
obstructing the participation of foreign companies in public tendering.

Some consider Putins vision for the Russian pharmaceutical industry to be unrealistically ambitious, perhaps even unlikely. However,
even if the pharmaceutical industry fails to meet the admittedly challenging targets, the government has clearly articulated its
determination to expand domestic manufacturers shares of the Russian market, and will continue to do so beyond 2020.

Russias domestic focus certainly presents a challenge for foreign competitors, but they should not entirely dissuaded from the
Russian market. Instead, foreign manufacturers should see this as an opportunity to invest more directly in Russia, as many have.
Since the introduction of Pharma 2020, manufacturers including the likes of Pfizer, Novartis, Roche and others have announced
plans to open manufacturing plants in Russia and to form partnerships with Russian companies. The Russian market presents a
lucrative opportunity for pharmaceutical manufacturers, and foreign manufacturers are better off working within the system instead of
eschewing it.

Additional information on market access in Russia and other countries can be found at Decision Resources Groups Global Market
Access Solution.
Source: (

Diseases (1)

Health Awareness (1)

Industry News (5)

Uncategorized (1)

Diosmin/Hesperidin Indian drug

manufacturing sector

medical treatment Russia

Russian Pharma

Russian pharmaceutical company

Russia quality medicines

Russias pharma

Russias pharmaceutical manufacturing

taj pharmaceuticals products

taj pharma cis taj pharma news

taj pharma products 2/4
7/3/2017 Pharma 2020: Russia Marching Towards Self-sufficiency?

Enter your e-mail address

Taj Pharma Group


Like Page Watch Video

Be the rst of your friends to like this

Discover the latest pharmaceutical

industry news updated, reliable news and
updated analysis on Healthcare Industry

Diseases (1) Taj Pharma Launches VENOSTOR

Health Awareness (1) (Diosmin/Hesperidin Tablets) Unique

Taj Pharma CIS ( ) offers a Natural Formula

Industry News (5)
range of comprehensive product
registration, marketing authorization, in- Uncategorized (1) Pharmaceuticals in Russia Pharma
licensing and out-licensing of
2020: From vision to decision |
pharmaceuticals products; and holds
expertise to register pharmaceuticals
products from formulation design up to
international products registration and Pharma 2020: Russia Marching Towards
Marksistsky lane 6, office 221,
What Russian pharma requires to grow
Moscow, 109147, Russia

+7 (495) 726-26-69 globally

Russian pharmaceutical market may grow

by 8% in 2016 3/4
7/3/2017 Pharma 2020: Russia Marching Towards Self-sufficiency?

Taj Pharma Russia & CIS ( ) | Copyright All Rights Reserved Site Map Terms and Conditions Privacy Policy Legal Notice 4/4